Common bile-duct stones and acute cholangitis: symptoms, ERCP, drainage and safety

Common bile-duct stones, also called choledocholithiasis, are stones in the duct that carries bile towards the small bowel. Acute cholangitis is infection involving the bile ducts, often with obstructed drainage, and can become an emergency. Confidence is high that suspected infection with blockage needs prompt assessment; hospital support, antibiotics and a plan to restore drainage have separate purposes. Duct-stone treatment; Infected obstruction.

Table of contents

• Evidence summary
• What are choledocholithiasis and acute cholangitis?
• Why obstructed bile, infection and pancreatic complications matter
• Hospital care, antibiotics, duct clearance and temporary biliary stents
• Diet, stone-dissolving prescriptions and “bile support” supplements
• Ultrasound, liver tests, MRCP, EUS and therapeutic ERCP
• Emergency symptoms and warning signs after ERCP or drainage
• Blood thinners, diabetes treatment, allergies and procedural preparation
• Frailty, pregnancy, previous procedures and suspected sepsis
• ERCP, percutaneous drainage and the follow-up plan after treatment
• Why laboratory “bile flow” effects do not prove human duct clearance
• Funding and source roles
• Frequently asked questions
• Sources and funding notes

Evidence summary

Clinical guidance, human outcome research and funding independence answer different questions. The guidance below explains care; it does not independently reproduce the trials behind a medicine or supplement.

What are choledocholithiasis and acute cholangitis?

The liver makes bile; ducts carry it to the small bowel, and the gallbladder stores it. A stone in the common duct can obstruct that route. Cholangitis concerns infected ducts, while cholecystitis concerns an inflamed gallbladder. The location matters when the team explains the diagnosis and proposed procedure. Bile flow and blockage; Duct infection.

These conditions can overlap, but a gallstone finding alone does not mean that every organ is inflamed or infected. A useful question is: are there stones in the gallbladder, the common duct, or both, and is there evidence of infection? Assessment of different structures.

This guide addresses stone-related duct obstruction and acute infection. A narrowed duct after surgery or a tumour can also block bile flow and requires a different cause-specific assessment. Cholangitis is not itself proof of cancer. Other obstruction causes.

Why obstructed bile, infection and pancreatic complications matter

Blocked bile drainage can produce jaundice. When an obstructed system becomes infected, a person can develop fever, shaking chills and serious illness. Restoring flow addresses a different problem from suppressing bacteria, which explains why drainage and antibiotics may both be discussed. Obstruction and infection.

A stone-related blockage can also affect the pancreas. Report pain that changes, vomiting and any yellowing of the eyes or skin; a previous label of uncomplicated gallstones should not prevent reassessment of a new illness. Related organs and changing symptoms.

Sepsis is a life-threatening reaction to infection. New confusion, slurred speech, breathing difficulty or unusually pale, blue or blotchy skin needs emergency help. Do not wait to assemble a complete list of pain, fever and jaundice before seeking care. Emergency infection signs.

Hospital care, antibiotics, duct clearance and temporary biliary stents

Serious infection is treated in hospital. Care may include intravenous antibiotics and fluids, oxygen when needed, and monitoring of the response. The medical team decides treatment from the illness, tests, allergies and other conditions; a webpage cannot choose an antibiotic or outpatient waiting period. Hospital support.

For common-duct stones, NICE describes duct clearance with laparoscopic gallbladder removal, including when a confirmed duct stone is symptom-free. Clearance can occur surgically during removal or by ERCP before or during surgery. This differs from advice about incidental stones confined to a normal gallbladder. Different stone locations and pathways.

If ERCP cannot clear the duct, NICE recommends a biliary stent as a temporary measure until definitive endoscopic or surgical clearance. Ask what remains in place, why another procedure is required, and who will arrange it. A stent insertion is not automatically complete stone clearance. Temporary stenting and definitive management.

The treatment sequence depends on urgency, anatomy, available expertise and individual suitability. Ask which problem the immediate intervention treats and what the subsequent decision will be; do not transfer an elective schedule to a new suspected infection.

Diet, stone-dissolving prescriptions and “bile support” supplements

Prescription dissolution therapy has a selected role for particular cholesterol stones and can take months or years. It is different from urgent management of infected obstruction. An over-the-counter bile acid, enzyme or herbal product should not be treated as an equivalent intervention. Selected dissolution context.

No financially cleared human evidence reviewed here establishes that a gallbladder flush, detox, probiotic or digestive supplement clears a common-duct stone or treats acute cholangitis. A change in discomfort or a laboratory marker cannot demonstrate restored drainage.

Give the team supplement names and ingredient lists. Products vary and can interact with medicines or procedural care. “Natural” does not settle suitability around an endoscopy or operation. Supplement and procedure safety.

Ask for a nutrition plan if illness has interrupted eating, and follow the service’s own instructions about when food and drink can resume. Avoid using a restrictive diet as a substitute for the planned duct investigation or treatment. Individual recovery instructions.

Ultrasound, liver tests, MRCP, EUS and therapeutic ERCP

Assessment combines history, examination, blood tests and imaging. Laboratories can indicate infection or inflammation; ultrasound can identify gallstones, while MRI can show duct stones. A result should be interpreted with symptoms and the suspected site of obstruction. Laboratory and imaging roles.

NICE recommends considering MRCP when ultrasound has not detected a common-duct stone but the duct is dilated and/or liver tests are abnormal. EUS may be considered when MRCP does not allow a diagnosis. Neither instruction means that everyone should book the same test independently. Selected MRCP and EUS pathway.

ERCP combines endoscopy and X-ray techniques and is mainly used to treat a duct problem, or when treatment is expected during the test. Other investigations may answer a diagnostic question without ERCP. Ask whether the next procedure aims to identify a cause, remove a stone, sample tissue or drain bile. Diagnostic versus therapeutic roles.

Persistent abnormalities after an intervention need explanation. Request the actual report and next plan rather than assuming that an improved symptom or a completed scope settles every remaining stone, narrowing or infection.

Emergency symptoms and warning signs after ERCP or drainage

Abdominal pain lasting more than 30 minutes needs urgent advice. Sudden severe pain, back-spreading pain with vomiting, fever or shivering, or jaundice warrants emergency assessment. These signs indicate possible serious illness; they do not establish one diagnosis remotely. Current gallstone warnings.

After ERCP, severe or worsening abdominal pain, fever, black stools, jaundice or vomiting that will not stop requires prompt contact with the service or emergency assessment. Take the procedure report when seeking help and explain when the intervention occurred. Post-ERCP warnings.

Percutaneous drain information advises emergency help for fever, abdominal pain, a tube moving out of position or fluid leaking around it. Do not try to reinsert a tube. Keep the urgent contact plan available to the person helping at home. Drain emergencies.

ERCP can cause pancreatitis, infection, bleeding or perforation; serious complications require clinical treatment. Consent should explain the material risks and alternatives in the actual circumstances, without converting a general page into a personal percentage. Procedure risks.

Blood thinners, diabetes treatment, allergies and procedural preparation

Tell the endoscopy team about prescription drugs, over-the-counter painkillers, supplements, allergies and previous reactions. Blood-thinning and diabetes treatment can require an individual plan. Do not stop a medicine solely because a general webpage lists it as relevant. Medication review.

Discuss possible pregnancy, contrast reactions and conditions affecting sedation with the treating team. Request written instructions tailored to the procedure and any acute illness. Different procedures and services can have different preparation requirements. Preparation discussion.

Confirm what to continue, what to withhold, when to restart it, and who to contact if instructions conflict. The service should also specify fasting; this guide provides no personalised fasting duration or medication interruption schedule. Service-led preparation.

Bring the medicine list and relevant reports to follow-up. If a discharge changes treatment, ensure that the clinician managing the ongoing condition has the updated plan.

Frailty, pregnancy, previous procedures and suspected sepsis

Give the team a history of abdominal operations, prior ERCP, stents or drainage tubes. Request an explanation of how the anatomy and previous procedures affect the proposed route. A generic description cannot establish whether the next intervention is suitable. Individual procedure context.

Possible pregnancy should be discussed before endoscopy and imaging. It does not justify a blanket internet decision that all investigation is forbidden or that all radiation is safe; the clinical team must assess the illness and procedure. Pregnancy disclosure.

Older people, people with weakened immunity and those pregnant or recently pregnant can be particularly vulnerable to serious infection. Tell the team about these circumstances promptly; new confusion or breathing difficulty needs emergency help. Risk and triage context.

Ask how support needs, communication requirements and the person’s priorities will be incorporated into consent, recovery and follow-up. Make these practical needs explicit before discharge.

ERCP, percutaneous drainage and the follow-up plan after treatment

During ERCP, an endoscopist may open the duct outlet, extract stones, take samples or place a stent. The report should state what was actually achieved. Ask whether stones remain, whether a stent was inserted and what requires another appointment. Possible interventions.

When an endoscopic route is unsuitable or unsuccessful, percutaneous drainage may be discussed. A radiologist uses imaging to pass a tube through the skin and liver into the duct. PTC refers to the contrast imaging performed through that route. This is not gallbladder removal. Through-liver drainage.

A drain may empty to an external bag, cross the blockage or later be capped; its removal timing belongs to the treating team. Obtain staff teaching, supplies and written follow-up, and avoid manipulating or flushing it from online instructions. Individual tube care and removal.

Sedation or anaesthesia can require an escort and support at home. Arrange the service’s requested help and follow its instructions for activity, eating and medicine resumption. Confirm who will explain any pending tissue result or repeat-procedure decision. Recovery and continuing care.

Why laboratory “bile flow” effects do not prove human duct clearance

Animal experiments, in-vitro antibacterial activity and changes in bile composition do not establish that a supplement clears an obstructed human duct or prevents sepsis. Those claims are excluded from the treatment verdict. Relevant human outcomes include illness resolution, definitive clearance, recurrence, further procedures and harms.

A meaningful comparison must match the decision: a silent gallbladder stone, a confirmed common-duct stone and infected obstruction are different situations. Evidence should describe eligibility, the intervention, follow-up and complications rather than combining them as one “gallstone cure”.

Government education and guideline recommendations explain clinical roles here. They do not clear every contributing expert or underlying trial. No numerical superiority claim for a drug, device or drainage route is adopted as independent efficacy.

Funding and source roles

National NHS information, a London hospital provider, NICE and NIH have different financial chains. The table traces institutional accounts and an acknowledged expert’s later research-support disclosure; complete page and trial allocations remain unresolved.

NIDDK gallstone material is November 2017 background. The ERCP page is January 2024 and its outside-expert commercial connection is disclosed. Older or overbroad provider wording is not converted into a universal procedure recommendation.

Frequently asked questions

Is cholangitis the same as cholecystitis? No. Cholangitis concerns the bile ducts; cholecystitis concerns the gallbladder. Confirm the location and infection assessment. Duct condition.

Can a duct stone need treatment without symptoms? NICE distinguishes common-duct stones from incidental gallbladder stones and describes clearance for both symptomatic and asymptomatic duct stones. Stone-location pathway.

Does ERCP remove the gallbladder? No. It can treat a duct problem; gallbladder removal is another procedure. Different interventions.

Is a biliary stent always permanent? No. In the NICE incomplete-clearance pathway it is temporary until definitive treatment; obtain the actual follow-up plan. Temporary stent role.

Can supplements replace hospital treatment? No cleared acute-treatment benefit is established here. Ingredient and medicine interactions also need disclosure. Safety context.

Sources and funding notes

Reviewed 4 October 2026. This guide distinguishes choledocholithiasis, acute cholangitis, gallbladder disease, diagnostic imaging, therapeutic ERCP and percutaneous bile-duct drainage. NHS gallstones was reviewed 11 August 2025 and sepsis 14 May 2026. NIDDK gallstone pages are November 2017; ERCP January 2024. NICE CG188 is a 2014 pathway, checked in original indexed recommendations/priorities and full-guideline recommendation list after direct access errors, not a new 2026 guideline. Guy’s and St Thomas’ ERCP series is September 2024; its duct-drainage series November 2023, due November 2026. Its own 2025–2026 accounts were checked. The NIDDK ERCP page acknowledges Forsmark and Novikov; a separate 2024 original discloses Forsmark’s AbbVie research support, without establishing earlier page payment. Overbroad provider MRI-implant, diagnostic-first, only-alternative and pregnancy statements are not adopted; licensed-image credit is not treated as proof of page sponsorship. No personal antibiotic, fasting, medication interruption, home tube manipulation or clearance/removal timetable is supplied. Clinical guidance provides context; corporate efficacy, animal/in-vitro claims and financially uncleared comparative outcomes do not determine an independent verdict.

1. NHS: Gallstones — Current abdominal-pain, fever/shivering and jaundice triage; gallstones can be silent or cause complications.
2. NHS: Sepsis — Emergency infection-related illness and hospital treatment context; symptoms are not a home diagnostic checklist.
3. NIDDK: Gallstone symptoms and causes — Duct obstruction, liver/pancreatic involvement and symptom changes; November 2017 background.
4. NIDDK: Gallstone diagnosis — History, laboratories and imaging roles, including ultrasound and duct MRI; no universal accuracy ranking.
5. NIDDK: Gallstone treatment — Distinct common-duct ERCP, gallbladder removal and slow prescription dissolution roles; older background, not a current efficacy ranking.
6. NIDDK: ERCP information — Therapeutic ERCP role and selected diagnostic alternatives, medicine disclosure and procedural warning signs. Later interests do not establish industry payment for the earlier page.
7. NICE: CG188 original recommendations — Original 2014 pathway for common-duct stone clearance, temporary stents and diagnostic MRCP/EUS; indexed NICE PDF checked after direct retrieval error. Clinical guidance, not independently cleared comparative efficacy or personal suitability.
8. NICE: CG188 implementation priorities — Duct clearance and gallbladder-removal pathway, distinct from symptom-free stones confined to a normal gallbladder; original indexed text, no new 2026 clinical review claimed. Clinical guidance, not independently cleared comparative efficacy or personal suitability.
9. NICE: CG188 full 2014 guideline — Original indexed recommendation list for selected MRCP/EUS diagnosis; no pooled accuracy or financially uncleared comparative outcome adopted. Clinical guidance, not independently cleared comparative efficacy or personal suitability.
10. Guy’s and St Thomas’: ERCP overview — Anatomy, obstruction causes, selected therapeutic role and material risks. Overbroad diagnostic-first, MRI-implant and only-alternative statements are excluded.
11. Guy’s and St Thomas’: Having ERCP — Preparation, consent, sphincterotomy, stone extraction and stents. Local fasting/medicine/antibiotic schedules and a future-stone-passage guarantee are not generalised.
12. Guy’s and St Thomas’: Recovery after ERCP — Post-procedure support, instructions, follow-up and severe pain/fever/bleeding warnings; not a fixed recovery schedule.
13. Guy’s and St Thomas’: Draining blocked bile ducts — Obstructed infected ducts, selected percutaneous route and risks. Categorical radiation/pregnancy wording is not adopted.
14. Guy’s and St Thomas’: Having percutaneous biliary drainage — Image-guided through-liver drainage, PTC terminology and internal/external tube possibilities; no universal preparation regimen.
15. Guy’s and St Thomas’: After percutaneous biliary drainage — Drain follow-up, individual removal/capping and emergency pain/fever/displacement/leakage; no self-flushing or reinsertion instructions.
16. Guy’s and St Thomas’: own 2025–2026 accounts — Provider-specific financial provenance; national NHS budget is not substituted for hospital accounts.
17. NICE: own 2025–2026 accounts — Guideline developer funding, separate from treatment efficacy.
18. 2024 NIDDK pancreatitis workshop: original disclosures — Outside-expert financial provenance only; later disclosure is not proof of sponsorship of the January 2024 ERCP page.
19. NCCIH: using supplements wisely — Ingredient differences, interactions and surgical disclosure; no demonstration of clearing an infected duct.
20. NHS England: national accounts — Funding provenance for national patient education only.
21. NIDDK: budget and legislative documentation — Federal publisher provenance, separate from contributing experts and trials.
22. NCCIH: congressional-budget document — Supplement-education financial provenance only.

Educational information reviewed 4 October 2026. This guide supports an informed clinical discussion; it does not diagnose an individual or provide a personal treatment regimen.